PHAXIAM Therapeutics S.A. (PHXM) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    PHAXIAM Therapeutics S.A.

    NASDAQ: PHXM · Real-Time Price · USD
    3.10
    -0.17 (-5.20%)
    At close: Mar 08, 2024, 10:00 PM

    PHAXIAM Therapeutics S.A. Income Statement

    Financials in EUR. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a
    Cost of Revenue
    		 1.61M 2.91M 5.38M
    Gross Profit
    		 -1.61M -2.91M -5.38M
    Operating Income
    		 -25.42M -32.08M -56.52M
    Interest Income
    		 259K 4.45M 13K
    Pretax Income
    		 -24.73M 293K -53.8M
    Net Income
    		 -23.49M -227K -53.8M
    Selling & General & Admin
    		 13.97M 13.89M 15.1M
    Research & Development
    		 9.84M 15.91M 40.22M
    Other Expenses
    		 n/a n/a n/a
    Operating Expenses
    		 23.81M 27.15M 56.52M
    Interest Expense
    		 196K 1.36M 2.14M
    Selling & Marketing Expenses
    		 n/a n/a n/a
    Cost & Expenses
    		 25.42M 32.08M 60.7M
    Income Tax Expense
    		 -1.25M 521K 2K
    Shares Outstanding (Basic)
    		 5.08M 3.1M 2.37M
    Shares Outstanding (Diluted)
    		 5.08M 3.1M 2.37M
    EPS (Basic)
    		 -4.62 -0.1 -22.7
    EPS (Diluted)
    		 -4.62 -0.1 -22.7
    EBITDA
    		 -23.81M -22.69M -47.45M
    EBIT
    		 -24.54M -6.37M -53.2M
    Depreciation & Amortization
    		 1.61M 2.91M 5.38M

    Add to Watchlist